Sign in
4

Changes in Ownership

Dianthus Therapeutics, Inc. /DE/ Filed Acc 0001992260-26-000006

EVP, Head of R&D sold 26,530 shares at an average $90.62 ($2,404,077)

  • EVP, Head of R&D acquired 26,530 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Randhawa Simrat EVP, Head of R&D 2026-06-01 Option exercise 10b5-1 +3,998 $8.44 $33,743 7,998 D
Randhawa Simrat EVP, Head of R&D 2026-06-01 Option exercise 10b5-1 +6,908 $17.88 $123,515 14,906 D
Randhawa Simrat EVP, Head of R&D 2026-06-01 Option exercise 10b5-1 +6,249 $21.77 $136,041 21,155 D
Randhawa Simrat EVP, Head of R&D 2026-06-01 Option exercise 10b5-1 +9,375 $22.07 $206,906 30,530 D
Randhawa Simrat EVP, Head of R&D 2026-06-01 Sale 10b5-1 −5,428 $89.72 $487,000 25,102 D
Randhawa Simrat EVP, Head of R&D 2026-06-01 Sale 10b5-1 −16,943 $90.72 $1,537,069 8,159 D
Randhawa Simrat EVP, Head of R&D 2026-06-01 Sale 10b5-1 −4,159 $91.37 $380,008 4,000 D
Derivatives
Randhawa Simrat EVP, Head of R&D 2026-06-01 Option exercise · Stock Option (Right to Buy) 10b5-1 −3,998 0 D
Randhawa Simrat EVP, Head of R&D 2026-06-01 Option exercise · Stock Option (Right to Buy) 10b5-1 −6,908 64,276 D
Randhawa Simrat EVP, Head of R&D 2026-06-01 Option exercise · Stock Option (Right to Buy) 10b5-1 −6,249 47,925 D
Randhawa Simrat EVP, Head of R&D 2026-06-01 Option exercise · Stock Option (Right to Buy) 10b5-1 −9,375 96,875 D
Open-market sales · 26,530 sh · avg $90.62 · $2,404,077
Loading xslF345X06/ownership.xml…